Radiopharmaceutical CDMO/CMO Services Market
完整報告名稱與涵蓋範圍
Radiopharmaceutical CDMO/CMO Services Market Size, Share & Trends Analysis Report, By Service Type (Radiolabelling and Drug Product Manufacturing, Radiochemistry Process Development, Analytical, Quality Control and Release Testing, Isotope Sourcing and Supply Chain Management, Regulatory and Clinical Trial Supply Support), By Radionuclide (Lutetium-177, Actinium-225 and Other Alpha Emitters, Fluorine-18 and Gallium-68 Diagnostics, Iodine-131, Yttrium-90 and Other Radionuclides), By Application (Therapeutic Radiopharmaceuticals, Diagnostic and Theranostic Imaging Agents), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The radiopharmaceutical CDMO/CMO services market covers outsourced development and manufacturing of radiolabelled therapeutics and diagnostics, including radiochemistry process development, GMP radiolabelling and drug product manufacture, analytical release testing, isotope sourcing and clinical trial supply management. It excludes captive in-house manufacturing by pharmaceutical companies and the isotope-supply business itself except where a provider bundles isotopes with manufacturing services.
Outsourcing demand has surged as radioligand therapy pipelines have broadened beyond a handful of large sponsors to dozens of biotechnology companies that lack radiation-licensed facilities, hot cells and the specialised quality systems required for short-lived products. The service model differs sharply from conventional CDMOs: doses must be manufactured against a decay clock, distributed through regional networks and often produced in multiple sites to guarantee patient scheduling. Providers are responding with new alpha-capable suites, integrated isotope-plus-manufacturing offers, automated synthesis platforms and North American and European network expansions, while sponsors increasingly negotiate long-term capacity reservations.
North America and Europe dominate both sponsor demand and provider capacity, with Asia Pacific building domestic supply in Japan, China, South Korea and Australia. Competition combines isotope producers integrating forward, nuclear pharmacy networks integrating backward, dedicated radiopharmaceutical CDMOs and large pharmaceutical groups that offer surplus capacity.
The InsightAce study provides US$ revenue forecasts for every service type, radionuclide, application and end user and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radiopharmaceutical CDMO/CMO Services Market Snapshot
Chapter 4. Global Radiopharmaceutical CDMO/CMO Services Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Service Type Estimates & Trend Analysis
5.1. Service Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Service Type:
5.2.1. Radiolabelling and Drug Product Manufacturing
5.2.2. Radiochemistry Process Development
5.2.3. Analytical, Quality Control and Release Testing
5.2.4. Isotope Sourcing and Supply Chain Management
5.2.5. Regulatory and Clinical Trial Supply Support
Chapter 6. Market Segmentation 2: By Radionuclide Estimates & Trend Analysis
6.1. Radionuclide & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Radionuclide:
6.2.1. Lutetium-177
6.2.2. Actinium-225 and Other Alpha Emitters
6.2.3. Fluorine-18 and Gallium-68 Diagnostics
6.2.4. Iodine-131, Yttrium-90 and Other Radionuclides
Chapter 7. Market Segmentation 3: By Application Estimates & Trend Analysis
7.1. Application & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
7.2.1. Therapeutic Radiopharmaceuticals
7.2.2. Diagnostic and Theranostic Imaging Agents
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Pharmaceutical and Biotechnology Companies
8.2.2. Academic and Clinical Research Sponsors
Chapter 9. Radiopharmaceutical CDMO/CMO Services Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Curium
11.2. ITM Isotope Technologies Munich SE
11.3. Eckert & Ziegler SE
11.4. NorthStar Medical Radioisotopes, LLC
11.5. SHINE Technologies, LLC
11.6. Cardinal Health, Inc.
11.7. Jubilant Radiopharma
11.8. PharmaLogic Holdings Corp.
11.9. SOFIE Biosciences, Inc.
11.10. Evergreen Theragnostics, Inc.
11.11. Isotopia Molecular Imaging Ltd.
11.12. BWXT Medical Ltd.
11.13. Nucleus RadioPharma, Inc.
11.14. Bayer AG (Radiopharmaceutical Manufacturing)
11.15. Novartis AG
圖表清單 List of Tables & Figures
Table 1. Global Radiopharmaceutical CDMO/CMO Services Market Revenue Forecast by Service Type, 2026-2035 (US$ Mn)
Figure 1. Global Radiopharmaceutical CDMO/CMO Services Market Segmentation Overview
Table 2. Global Radiopharmaceutical CDMO/CMO Services Market Revenue Forecast by Radionuclide, 2026-2035 (US$ Mn)
Figure 2. Global Radiopharmaceutical CDMO/CMO Services Market Share by Service Type, 2026 & 2035
Table 3. Global Radiopharmaceutical CDMO/CMO Services Market Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 3. Radiopharmaceutical CDMO Service Model Under Radioactive Decay Constraints
Table 4. Global Radiopharmaceutical CDMO/CMO Services Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Global Radiopharmaceutical CDMO/CMO Services Market Share by Radionuclide, 2026 & 2035
Table 5. North America Radiopharmaceutical CDMO/CMO Services Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Alpha-Capable Manufacturing Capacity Additions by Provider and Region, 2024-2028
Table 6. Europe Radiopharmaceutical CDMO/CMO Services Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Radiopharmaceutical CDMO/CMO Services Growth Opportunity Analysis
Table 7. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Outsourcing Penetration Across Radioligand Therapy Sponsors by Company Size
Table 8. Latin America Radiopharmaceutical CDMO/CMO Services Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Radiopharmaceutical CDMO/CMO Services Market Participants
Table 9. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們